AstraZeneca relies on its R&D center in Shanghai to promote innovation and will launch at least 100 new medicines in China in the next five years, achieving mutual interests with Chinese collaborators, said Sharon Barr, EVP of Biopharmaceuticals R&D of global pharmaceutical giant AstraZeneca, in an interview with CGTN.
